Cutaneous drug reactions in children: An update

Pediatric Drugs

Volumn 15, Issue 6, 2013, Pages 493-503

  Heelan, Kara ^a   Shear, Neil H ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ANDROGEN; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; BETA LACTAM ANTIBIOTIC; CALCIUM CHANNEL BLOCKING AGENT; CEFACLOR; CEPHALOSPORIN DERIVATIVE; CORTICOSTEROID; COTRIMOXAZOLE; DERMATOLOGICAL AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IODIDE; ISONIAZID; LAXATIVE; LITHIUM; MACROLIDE; MINOCYCLINE; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; ORAL CONTRACEPTIVE AGENT; PENICILLIN DERIVATIVE; PHENYTOIN; PRESCRIPTION DRUG; SULFONAMIDE; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG;

ACNE; ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ANGIONEUROTIC EDEMA; ANTIBIOTIC THERAPY; BULLOUS PEMPHIGOID; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DRESS SYNDROME; DRUG ERUPTION; DRUG FEVER; ERYTHEMA MULTIFORME; FEVER; FIXED DRUG ERUPTION; HAND FOOT SYNDROME; HIDRADENITIS; HUMAN; LUPUS LIKE SYNDROME; MALAISE; PEMPHIGUS; PRIORITY JOURNAL; RASH; REVIEW; SERUM SICKNESS LIKE REACTION; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TYPHUS; URTICARIA;

CHILD; DIAGNOSIS, DIFFERENTIAL; DRUG ERUPTIONS; HUMANS; SKIN DISEASES, VESICULOBULLOUS; URTICARIA;

EID: 84890545779     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/s40272-013-0039-z     Document Type: Review

References (98)

1. Segal AR, Doherty KM, Leggott J, Zlotoff B. Cutaneous reactions to drugs in children. Pediatrics. 2007;120(4):e1082-96.
2. Star K, Noren GN, Nordin K, Edwards IR. Suspected adverse drug reactions reported for children worldwide: an exploratory study using VigiBase. Drug Saf. 2011;34(5):415-28.
3. Castro-Pastrana LI, Ghannadan R, Rieder MJ, Dahlke E, Hayden M, Carleton B. Cutaneous adverse drug reactions in children: an analysis of reports from the Canadian Pharmacogenomics Network for Drug Safety (CPNDS). J Popul Ther Clin Pharmacol. 2011;18:e106-20.
4. Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol. 2001;52(1):77-83.
5. Gallagher RM, Mason JR, Bird KA, Kirkham JJ, Peak M, Williamson PR, et al. Adverse drug reactions causing admission to a paediatric hospital. PLoS One. 2012;7(12):e50127.
6. Smyth RM, Gargon E, Kirkham J, Cresswell L, Golder S, Smyth R, et al. Adverse drug reactions in children - a systematic review. PLoS One. 2012;7(3):e24061.
7. Menniti-Ippolito G, Raschetti R, Da Cas R, Giaquinto C, Cantarutti L. Active monitoring of adverse drug reactions in children. Italian Paediatric Pharmacosurveillance Multicenter Group. Lancet. 2000;355(9215):1613-4.
8. Ibia EO, Schwartz RH, Wiedermann BL. Antibiotic rashes in children: a survey in a private practice setting. Arch Dermatol. 2000;136(7):849-54.
9. Pirmohamed M, Friedmann PS, Molokhia M, Loke YK, Smith C, Phillips E, et al. Phenotype standardization for immune-mediated drug-induced skin injury. Clin Pharmacol Ther. 2011;89(6):896-901.
10. Nigen S, Knowles SR, Shear NH. Drug eruptions: approaching the diagnosis of drug-induced skin diseases. J Drugs Dermatol. 2003;2(3):278-99.
11. Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA. 1986;256(24):3358-63.
12. Naranjo CA, Shear NH, Lanctot KL. Advances in the diagnosis of adverse drug reactions. J Clin Pharmacol. 1992;32(10):897-904.
13. Stern RS. Clinical practice: exanthematous drug eruptions. N Engl J Med. 2012;366(26):2492-501.
14. Yawalkar N. Maculopapular drug eruptions. Basel: Karger; 2007. p. 242-51.
15. Crowson AN, Magro CM. Recent advances in the pathology of cutaneous drug eruptions. Dermatol Clin. 1999; 17(3):537-60, viii.
16. Carroll MC, Yueng-Yue KA, Esterly NB, Drolet BA. Drug-induced hypersensitivity syndrome in pediatric patients. Pediatrics. 2001;108(2):485-92.
17. Kress DW. Pediatric dermatology emergencies. Curr Opin Pediatr. 2011;23(4):403-6.
18. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331(19):1272-85.
19. Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, et al. The DRESS syndrome: a literature review. Am J Med. 2011;124(7):588-97.
20. Chen YC, Chiu HC, Chu CY. Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases. Arch Dermatol. 2010;146(12):1373-9.
21. Eshki M, Allanore L, Musette P, Milpied B, Grange A, Guillaume JC, et al. Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. Arch Dermatol. 2009;145(1):67-72.
22. Hunter EB, Johnston PE, Tanner G, Pinson CW, Awad JA. Bromfenac (Duract)-associated hepatic failure requiring liver transplantation. Am J Gastroenterol. 1999;94(8):2299-301.
23. Gupta A, Eggo MC, Uetrecht JP, Cribb AE, Daneman D, Rieder MJ, et al. Drug-induced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides. Clin Pharmacol Ther. 1992;51(1):56-67.
24. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome: In vitro assessment of risk. J Clin Invest. 1988;82(6):1826-32.
25. Newell BD, Moinfar M, Mancini AJ, Nopper AJ. Retrospective analysis of 32 pediatric patients with anticonvulsant hypersensitivity syndrome (ACHSS). Pediatr Dermatol. 2009;26(5):536-46.
26. Tamayo-Sanchez L, Ruiz-Maldonado R, Laterza A. Acute annular urticaria in infants and children. Pediatr Dermatol. 1997;14(3):231-4.
27. Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol. 2001;137(6):765-70.
28. Twarog FJ. Urticaria in childhood: pathogenesis and management. Pediatr Clin N Am. 1983;30(5):887-98.
29. Bilbao A, Garcia JM, Pocheville I, Gutierrez C, Corral JM, Samper A, et al. Round table: urticaria in relation to infections [article in Spanish]. Allergol Immunopathol (Madr). 1999;27(2):73-85.
30. Smith PF, Corelli RL. Doxepin in the management of pruritus associated with allergic cutaneous reactions. Ann Pharmacother. 1997;31(5):633-5.
31. Poon M, Reid C. Do steroids help children with acute urticaria? Arch Dis Child. 2004;89(1):85-6.
32. Lawley TJ, Bielory L, Gascon P, Yancey KB, Young NS, Frank MM. A prospective clinical and immunologic analysis of patients with serum sickness. N Engl J Med. 1984;311(22):1407-13.
33. Kearns GL, Wheeler JG, Childress SH, Letzig LG. Serum sickness-like reactions to cefaclor: role of hepatic metabolism and individual susceptibility. J Pediatr. 1994;125(5 Pt 1):805-11.
34. Ashraf-Benson S, Wall GC, Veach LA. Serum sickness-like reaction associated with efalizumab. Ann Pharmacother. 2009;43(2):383-6.
35. Dreyfus DH, Randolph CC. Characterization of an anaphylactoid reaction to omalizumab. Ann Allergy Asthma Immunol. 2006;96(4):624-7.
36. Finger E, Scheinberg M. Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia. J Clin Rheumatol. 2007;13(2):94-5.
37. Gamarra RM, McGraw SD, Drelichman VS, Maas LC. Serum sickness-like reactions in patients receiving intravenous infliximab. J Emerg Med. 2006;30(1):41-4.
38. Grosen A, Julsgaard M, Christensen LA. Serum sickness-like reaction due to Infliximab reintroduction during pregnancy. J Crohns Colitis. 2013;7(5):e191.
39. Sarma N, Malakar S, Lahiri K, Banerjee U. Serum sickness like reaction with minocycline. Indian J Dermatol Venereol Leprol. 2004;70(1):43-4.
40. Katta R, Anusuri V. Serum sickness-like reaction to cefuroxime: a case report and review of the literature. J Drugs Dermatol. 2007;6(7):747-8.
41. Parra FM, Perez Elias MJ, Cuevas M, Ferreira A. Serum sickness-like illness associated with rifampicin. Ann Allergy. 1994;73(2):123-5.
42. Slama TG. Serum sickness-like illness associated with ciprofloxacin. Antimicrob Agents Chemother. 1990;34(5):904-5.
43. Ralph ED, John M, Rieder MJ, Bombassaro AM. Serum sickness-like reaction possibly associated with meropenem use. Clin Infect Dis. 2003;36(11):E149-51.
44. Brucculeri M, Charlton M, Serur D. Serum sickness-like reaction associated with cefazolin. BMC Clin Pharmacol. 2006;6:3.
45. Colton RL, Amir J, Mimouni M, Zeharia A. Serum sickness-like reaction associated with griseofulvin. Ann Pharmacother. 2004;38(4):609-11.
46. Park H, Knowles S, Shear NH. Serum sickness-like reaction to itraconazole. Ann Pharmacother. 1998;32(11):1249.
47. Waibel KH, Katial RK. Serum sickness-like reaction and bupropion. J Am Acad Child Adolesc Psychiatry. 2004;43(5):509.
48. Phillips EJ, Knowles SR, Shear NH. Serum sickness-like reaction associated with clopidogrel. Br J Clin Pharmacol. 2003;56(5):583.
49. Shapiro LE, Knowles SR, Shear NH. Fluoxetine-induced serum sickness-like reaction. Ann Pharmacother. 1997;31(7-8):927.
50. Aujero MP, Brooks S, Li N, Venna S. Severe serum sickness-like type III reaction to insulin detemir. J Am Acad Dermatol. 2011;64(6):e127-8.
51. Azik FM, Kanmaz G, Ileri T. Serum sickness-like syndrome after immunoglobulin M-enriched polyclonal immunoglobulin. Drug Metabol Drug Interact. 2010;25(1-4):49-50.
52. Harris A, Eswaran S, Bosworth B, Gambarin-Gelwan M, Scherl EJ. Mesalamine-induced pneumonitis and serum sickness-like reaction. Gastroenterol Hepatol (N Y). 2007;3(11):875-7.
53. Lee HS, Yule S, McKenzie A, Cross S, Reid T, Davidson R, et al. Hypersensitivity reactions to streptokinase in patients with high pre-treatment antistreptokinase antibody and neutralisation titres. Eur Heart J. 1993;14(12):1640-3.
54. Joubert GI, Hadad K, Matsui D, Gloor J, Rieder MJ. Selection of treatment of cefaclor-associated urticarial, serum sickness-like reactions and erythema multiforme by emergency pediatricians: lack of a uniform standard of care. Can J Clin Pharmacol. 1999;6(4):197-201.
55. Vial T, Pont J, Pham E, Rabilloud M, Descotes J. Cefaclor-associated serum sickness-like disease: eight cases and review of the literature. Ann Pharmacother. 1992 Jul-Aug;26(7-8):910-4.
56. Grammer LC. Cefaclor serum sickness. JAMA. 1996;275(15):1152-3.
57. Hurwitz RM. Steroid acne. J Am Acad Dermatol. 1989;21(6):1179-81.
58. Traupe H, von Muhlendahl KE, Bramswig J, Happle R. Acne of the fulminans type following testosterone therapy in three excessively tall boys. Arch Dermatol. 1988;124(3):414-7.
59. Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP) - a clinical reaction pattern. J Cutan Pathol. 2001;28(3):113-9.
60. Roujeau JC, Bioulac-Sage P, Bourseau C, Guillaume JC, Bernard P, Lok C, et al. Acute generalized exanthematous pustulosis: analysis of 63 cases. Arch Dermatol. 1991;127(9):1333-8.
61. Meadows KP, Egan CA, Vanderhooft S. Acute generalized exanthematous pustulosis (AGEP), an uncommon condition in children: case report and review of the literature. Pediatr Dermatol. 2000;17(5):399-402.
62. Ersoy S, Paller AS, Mancini AJ. Acute generalized exanthematous pustulosis in children. Arch Dermatol. 2004;140(9):1172-3.
63. Fernando SL. Acute generalised exanthematous pustulosis. Australas J Dermatol. 2012;53(2):87-92.
64. Schmid S, Kuechler PC, Britschgi M, Steiner UC, Yawalkar N, Limat A, et al. Acute generalized exanthematous pustulosis: role of cytotoxic T cells in pustule formation. Am J Pathol. 2002;161(6):2079-86.
65. De Silva B, Banney L, Uttley W, Luqmani R, Schofield O. Pseudoporphyria and nonsteroidal antiinflammatory agents in children with juvenile idiopathic arthritis. Pediatr Dermatol. 2000;17(6):480-3.
66. Lang BA, Finlayson LA. Naproxen-induced pseudoporphyria in patients with juvenile rheumatoid arthritis. J Pediatr. 1994;124(4):639-42.
67. Brenner S, Goldberg I. Drug-induced pemphigus. Clin Dermatol. 2011;29(4):455-7.
68. Cetkovska P, Pizinger K. Childhood pemphigus associated with montelukast administration. Clin Exp Dermatol. 2003;28(3):328-9.
69. Purvis DJ, Bhogal BS, Harper JI. Bullous pemphigoid in an infant using complementary medicine. Clin Exp Dermatol. 2009;34(2):195-8.
70. Fisler RE, Saeb M, Liang MG, Howard RM, McKee PH. Childhood bullous pemphigoid: a clinicopathologic study and review of the literature. Am J Dermatopathol. 2003;25(3):183-9.
71. Erbagci Z. Childhood bullous pemphigoid following hepatitis B immunization. J Dermatol. 2002;29(12):781-5.
72. Wojnarowska F, Marsden RA, Bhogal B, Black MM. Chronic bullous disease of childhood, childhood cicatricial pemphigoid, and linear IgA disease of adults: a comparative study demonstrating clinical and immunopathologic overlap. J Am Acad Dermatol. 1988;19(5 Pt 1):792-805.
73. Nantel-Battista M, Al Dhaybi R, Hatami A, Marcoux D, Desroches A, Kokta V. Childhood linear IgA bullous disease induced by trimethoprim- sulfamethoxazole. J Dermatol Case Rep. 2010;19:4(3):33-5.
74. Ho JC, Ng PL, Tan SH, Giam YC. Childhood linear IgA bullous disease triggered by amoxicillin-clavulanic acid. Pediatr Dermatol. 2007;24(5):E40-3.
75. Koh MJ, Tay YK. An update on Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Curr Opin Pediatr. 2009;21(4):505-10.
76. Finkelstein Y, Soon GS, Acuna P, George M, Pope E, Ito S, et al. Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Pediatrics. 2011;128(4):723-8.
77. Levi N, Bastuji-Garin S, Mockenhaupt M, Roujeau JC, Flahault A, Kelly JP, et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics. 2009;123(2):e297-304.
78. Sotozono C, Ueta M, Kinoshita S. Systemic and local management at the onset of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications. Am J Ophthalmol. 2010;149(2):354 (author reply 5).
79. Struck MF, Hilbert P, Mockenhaupt M, Reichelt B, Steen M. Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes. Intensive Care Med. 2010;36(1):22-32.
80. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428(6982):486.
81. Shiga S, Cartotto R. What are the fluid requirements in toxic epidermal necrolysis? J Burn Care Res. 2010;31(1):100-4.
82. Paquet P, Pierard GE. New insights in toxic epidermal necrolysis (Lyell's syndrome): clinical considerations, pathobiology and targeted treatments revisited. Drug Saf. 2010;33(3):189-212.
83. Hanken I, Schimmer M, Sander CA. Basic measures and systemic medical treatment of patients with toxic epidermal necrolysis. J Dtsch Dermatol Ges. 2010;8(5):341-6.
84. Inamo Y, Okubo T, Wada M, Fuchigami S, Hashimoto K, Fuchigami T, et al. Intravenous ulinastatin therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis in pediatric patients. Three case reports. Int Arch Allergy Immunol. 2002;127(1):89-94.
85. Mockenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges. 2009;7(2):142-60 (quiz 61-2).
86. Del Pozzo-Magana BR, Lazo-Langner A, Carleton B, Castro-Pastrana LI, Rieder MJ. A systematic review of treatment of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Popul Ther Clin Pharmacol. 2011;18:e121-33.
87. Khaled A, Kharfi M, Ben Hamida M, El Fekih N, El Aidli S, Zeglaoui F, et al. Cutaneous adverse drug reactions in children: a series of 90 cases. Tunis Med. 2012;90(1):45-50.
88. Sharma VK, Dhar S. Clinical pattern of cutaneous drug eruption among children and adolescents in north India. Pediatr Dermatol. 1995;12(2):178-83.
89. Ott H. Hypersensitivity reactions to drugs. Harper's textbook of pediatric dermatology, 3rd ed. New York: Wiley; 2011: 183.1-183.14.
90. Shiohara T. Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol. 2009;9(4):316-21.
91. Ozkaya E. Fixed drug eruption: state of the art. J Dtsch Dermatol Ges. 2008;6(3):181-8.
92. Shih IH, Huang YH, Yang CH, Yang LC, Hong HS. Childhood neutrophilic eccrine hidradenitis: a clinicopathologic and immunohistochemical study of 10 patients. J Am Acad Dermatol. 2005;52(6):963-6.
93. Shear NH, Knowles SR, Shapiro L, Poldre P. Dapsone in prevention of recurrent neutrophilic eccrine hidradenitis. J Am Acad Dermatol. 1996;35(5 Pt 2):819-22.
94. White-Koning M, Civade E, Geoerger B, Thomas F, Le Deley MC, Hennebelle I, et al. Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children. Clin Cancer Res. 2011;17(14):4862-71.
95. Arkachaisri T, Lehman TJ. Systemic lupus erythematosus and related disorders of childhood. Curr Opin Rheumatol. 1999;11(5):384-92.
96. Farver DK. Minocycline-induced lupus. Ann Pharmacother. 1997;31(10):1160-3.
97. Akin E, Miller LC, Tucker LB. Minocycline-induced lupus in adolescents. Pediatrics. 1998;101(5):926.
98. Finkel TH, Hunter DJ, Paisley JE, Finkel RS, Larsen GL. Drug-induced lupus in a child after treatment with zafirlukast (Accolate). J Allergy Clin Immunol. 1999;103(3 Pt 1):533-4.